CorMedix Inc（CRMD）の財務CRMDCorMedix Inc

Evaluating the bottom line, CorMedix Inc. maintains a gross margin of 75.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.10%, while the net margin is 25.50%. These profitability ratios, combined with a Return on Equity (ROE) of 54.93%, provide a clear picture of how effectively CRMD converts its operational activities into shareholder value.

In the context of the broader market, CRMD competes directly with industry leaders such as CBIO and STTK. With a market capitalization of $576.01M, it holds a significant position in the sector. When comparing efficiency, CRMD's gross margin of 75.66% stands against CBIO's 100.00% and STTK's N/A. Such benchmarking helps identify whether CorMedix Inc. is trading at a premium or discount relative to its financial performance.

CorMedix has shown strong revenue growth, with Q2 2026 revenue reported at $101.9 million, up from $39.7 million a year ago, and a gross margin of 75.66% in Q2 2026, indicating solid profitability. The company raised its FY26 adjusted EBITDA guidance to between $125 million and $140 million, reflecting confidence in future performance.